MiR-373-3p enhances the chemosensitivity of gemcitabine through cell cycle pathway by targeting CCND2 in pancreatic carcinoma cells

Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie
Wenjie HuZheng Sui

Abstract

This study aimed to detect the expression of miR-373-3p and CCND2 in gemcitabine-resistance pancreatic carcinoma (PC) cells, investigate the relationship between miR-373-3p and CCND2, and explore their effects on PC propagation, migration, invasion and apoptosis. R software was applied for analyzing differentially expressed genes (DEGs) in cell samples. The potential biological pathway was determined by Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis, based on R software. The gemcitabine-resistance PC cells were screened out using MTT assay, and they were applied in the next experiments. MiR-373-3p and CCND2 expression in GEM-PANC-1 cells were measured by qRT-PCR. After transfection, the expression of CCND2 protein was examined via western blot assay. Cells viability and apoptosis were confirmed by MTT proliferation assay and Flow cytometry, whereas cells migration and invasion were analyzed by transwell assay. The targeting relationship between miR-373-3p and CCND2 was identified by dual-luciferase reporter assay. MiR-373-3p was found to be low expressed in GEM-PANC-1 cells while CCND2 was highly expressed in GEM-PANC-1 cells. MiR-373-3p negatively regulated CCND2 expression through KEGG_Cell_Cycle_Signaling_Pa...Continue Reading

References

Jan 15, 2008·Nature Cell Biology·Qihong HuangReuven Agami
Jan 17, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Assia L AngelovaZahari Raykov
Jun 25, 2009·International Journal of Cancer. Journal International Du Cancer·Thomas GreitherHelge Taubert
Apr 8, 2010·Current Cancer Drug Targets·Asfar S AzmiRamzi M Mohammad
Jun 27, 2013·British Journal of Cancer·Y IwagamiY Doki
Oct 1, 2013·Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [et Al.]·Daisuke TakiuchiYuichiro Doki
Nov 15, 2013·Biomedical Journal·Alexandra Drakaki, Dimitrios Iliopoulos
Jan 9, 2014·International Journal of Oncology·Naotake FunamizuKatsuhiko Yanaga
Apr 22, 2014·Annals of Surgical Oncology·Kohei NakataMasao Tanaka
Apr 8, 2015·The Journal of Surgical Research·Paul A TosteTimothy R Donahue
May 21, 2015·Journal of Translational Medicine·Furong WeiJunfu Wang
Aug 2, 2017·Cancer Biomarkers : Section a of Disease Markers·Yongqiang HuaZhiqiang Meng

❮ Previous
Next ❯

Citations

Nov 16, 2019·Bioscience Reports·Wen-Cui LiJuan-Juan Zhang
Jul 17, 2020·Journal of Oncology·Cheng DingMenghua Dai
Nov 7, 2020·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·Zhengjun LinHe Huang
Oct 17, 2020·Journal of Immunology Research·Tao PengLixiang Zhou
Nov 10, 2021·Future Oncology·Mei-Qian WangSen-Lin Zhu
Nov 29, 2021·Chinese Medical Journal·Xiangyu ChuYinmo Yang

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Cell Migration

Cell migration is involved in a variety of physiological and pathological processes such as embryonic development, cancer metastasis, blood vessel formation and remoulding, tissue regeneration, immune surveillance and inflammation. Here is the latest research.